Serum Soluble Programmed Death Ligand 1 is Correlated with HBsAg Level and Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B

Abstract

The restoration of immune responses is thought as a complementary approach to the nucleos(t)ide analogue (NUC) therapy of chronic HBV infection. The antiviral immunity is negatively regulated by the programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) axis. Here, the soluble form of PD-L1 (sPD-L1) that represents the amount of PD-L1 expression cells was used as an indicator to investigate the involvement of this axis in chronic HBV infection, especially in the setting of NUC therapy. increased in NUC-treated patients. These results may be helpful in seeking for new therapeutic approaches to chronic HBV infection in the future.